Therapy Areas: Allergy
19 July 2019 - - The US Food and Drug Administration granted rare pediatric disease designation to LM-030, an investigational therapy licensed from Swiss drugmaker Novartis and ready to enter into piv...
17 July 2019 - - US-based biotechnology company Axial Biotherapeutics has dosed the first patient in its Phase 1b/2a clinical trial of AB-2004. In animal models, AB-2004 has demonstrated the ability t...
12 July 2019 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched an over-the-counter store-brand equivalent of Mucinex D Extended Release Tabl...
11 July 2019 - - One of US-based drug and vaccine developer CEL-SCI Corp.'s (NYSE American: CVM) key collaborators from Rush University Medical center, Dr. Adrienn Markovitz, an assista...
3 July 2019 - - The first patient has been enrolled in the Phase 1b/2 clinical study of VE416 in adults and adolescents with a history of peanut allergy, US-based clinical-stage company Vedanta Biosci...
3 July 2019 - Vedanta Biosciences, a subsidiary of PureTech Health, has enrolled its first patient in the Phase 1b/2 clinical study of VE416 in adults and adolescents with a history of peanut allergy,...
Related Headlines